IMS Health data for 2009 creates an interesting picture of global drug sales and growth in specific therapeutic classes. WBC (wbcbaltimore.com) has taken a look and found that the global picture is clearly different when compared to  U.S. pharmacy benefit plan sponsor drug spend.  In the U.S., antipsychotics were the leading therapeutic class with $14.6 billion in sales. Antilipididemics (like Lipitor, Crestor, simvastatin, etc.) with $14.3 billion is number two; acid reflux (Nexium, Prevacid, etc.) with $13.6 billion in sales comes in at number three; and antidepressants (Cymbalta, Effexor, etc.) holds down the number four spot with $9.9 billion in sales. Surprisingly, oncology agents, while number one globally in sales, ranks number six in the U.S.